Skip to main content

Table 1 Demographics of Patients with and without Adverse Cardiac Events with Immunotherapy

From: Cardiotoxicity risk factors with immune checkpoint inhibitors

 

Persons with Cardiac Events

n = 26

Persons without Cardiac Events

n = 512

P Value

Demographics

 Age, years [mean ± SD]

65 ± 8

66 ± 11

0.881

 Gender (F) n (%1)

16 (8.1%)

180 (92%)

0.011a

 Race

  Caucasian n (%1)

19 (4%)

449 (96%)

0.017b

  African American n (%1)

7 (12%)

50 (88%)

-

  Other

0

13 (2.5%)

-

Cardiovascular Disease Risk Factors

 BMI (kg/m2)

25 ± 6

26 ± 7

0.308

 Hypertension n (%1)

14 (4%)

307 (96%)

0.678

 Diabetes Mellitus,

Type II n (%1)

2 (7.7%)

87 (17%)

0.339

 Smoker n (%1)

22 (6%)

332 (94%)

0.062

Immune Checkpoint Inhibitors

 Pembrolizumab n (%1)

17 (7%)

226 (93%)

0.055

 Nivolumab n (%1)

8 (4%)

212 (96%)

0.383

 Ipilimumab n (%1)

0

39 (100%)

-

 Durvalumab n (%1)

1 (3%)

35 (97%)

0.847

Cardiovascular Medications prior to starting ICI

 Beta Blockers n (%1)

11 (7.2%)

141 (92.8%)

0.103

 ACE/ARB n (%1)

5 (4.1%)

118 (95.9%)

0.651

 Calcium Channel Blocker n (%1)

6 (5.4%)

106 (94.6%)

0.771

 Diuretic n (%1)

6 (6.9%)

81 (93.1%)

0.327

 Statin n (%1)

10 (5.9%)

159 (94.1%)

0.427

 No Cardiovascular Medications

6

  
  1. There were 26 patients with cardiac events and 34 events total
  2. 1Represents percentage of subgroup population with or without occurrence of event
  3. aChi-square comparing Females and Males
  4. bChi-square comparing Caucasian and African American race only